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We explored in a phase I/II clinical trial the combination of valproic acid (VPA), a clinically available histone deacetylase inhibitor, with
standard chemoimmunotherapy in patients with advanced melanoma, to evaluate its clinical activity, to correlate the clinical response
with the biological activity of VPA and to assess toxicity. Patients were treated initially with VPA alone for 6 weeks. The inhibition of
the target in non-tumour peripheral blood cells (taken as a potential surrogate marker) was measured periodically, and valproate
dosing adjusted with the attempt to reach a measurable inhibition. After the treatment with valproate alone, dacarbazine plus
interferon-a was started in combination with valproate. Twenty-nine eligible patients started taking valproate and 18 received
chemoimmunotherapy and are assessable for response. We observed one complete response, two partial remissions and three
disease stabilisations lasting longer than 24 weeks. With the higher valproate dosages needed to reach a measurable inhibition of the
target, we observed an increase of side effects in those patients who received chemoimmunotherapy. The combination of VPA and
chemoimmunotherapy did not produce results overtly superior to standard therapy in patients with advanced melanoma and toxicity
was not negligible, casting some doubts on the clinical use of VPA in this setting (at least in the administration schedule adopted).
British Journal of Cancer (2009) 100, 28–36. doi:10.1038/sj.bjc.6604817 www.bjcancer.com
& 2009 Cancer Research UK
Keywords: histone deacetylase inhibitor; epigenetic therapy; valproic acid; chemoimmunotherapy; melanoma
                                                 
Histone acetylation is dynamically regulated by the action of
histone acetylases (HATs) and deacetylases (HDACs), and it is
directly involved in the regulation of gene expression: hyper-
acetylated histones are found at expressed genes or at genes poised
for transcription, whereas hypoacetylated histones are found at
silent genes and in heterochromatin (Grunstein, 1997). Recent
studies have shown that HATs/HDACs may be involved in
acetylation/deacetylation of non-histone proteins (including cyto-
plasmic factors), which may modify functional properties of the
substrate (Minucci and Pelicci, 2006). Deregulation of acetylation
pathways may therefore exploit multiple strategies to lead to a
transformed cell phenotype, and HDAC-dependent mechanisms
have been involved in the pathogenesis of multiple tumours. For
this reason, HDAC inhibitors (HDACis) have been tested
extensively in vitro and in animal models of solid tumours. The
results have shown that indeed HDACis are able to induce growth
arrest, differentiation and/or apoptosis of essentially all tumour
cell lines tested and induce tumour regression in animal models
(Saunders et al, 1999; Marks et al, 2000). These observations have
triggered the beginning of clinical studies in cancer patients; in
some cases (i.e., T-cell cutaneous lymphoma), the results have
been extremely promising, leading to the introduction of HDACis
in the clinical practice (Piekarz et al, 2001; Byrd et al, 2005).
We have identified valproic acid (VPA), a commonly used
antiepileptic drug, as an HDACi (Gottlicher et al, 2001). Beside its
neurological effects (which are not due to its HDAC inhibitory
activity), VPA is able to inhibit directly, although weakly, HDACs
(Ki in the millimolar range). As it has been used for decades and it
is relatively ‘safe’, VPA has been therefore welcomed as a very
attractive drug to enter this area, and several clinical studies have
started to explore the potential of VPA as an anticancer therapy
(Arce et al, 2006; Atmaca et al, 2007; Bishton et al, 2007;
Candelaria et al, 2007; Munster et al, 2007; Rasheed et al, 2007,
2008).
In preclinical studies, VPA was used in murine models of acute
promyelocytic leukaemia, where it caused disease remission, and
in xenograft models of renal and lung metastasis, where it was
highly effective in reducing the number and size of metastasis
upon reinoculation of syngeneic mice with tumour cells (Gottlicher
et al, 2001; Insinga et al, 2005).
Molecular evidences have been obtained to support the use of
HDACis in the therapy of melanoma. Histone deacetylase
inhibitors have been shown to induce strong decrease in the
Received 7 August 2008; revised 3 November 2008; accepted 15
November 2008
*Correspondence: Dr A Rocca or Professor S Minucci or Dr A Testori;
E-mails: a.rocca@irst.emr.it or saverio.minucci@ifom-ieo-campus.it or
alessandro.testori@ieo.it
6These authors contributed equally to this work
7Current address: Congenia SRL, Via Adamello 16, Milan, Italy
British Journal of Cancer (2009) 100, 28–36
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
stumorigenic potential of melanoma-derived cell lines in animal
models (xeno-transplantation), and to induce proapoptotic path-
ways in melanoma cells lines (Facchetti et al, 2004; Boyle et al,
2005). Strikingly, it has been suggested that resistance of
melanoma cells to chemotherapy might – at least in some cases
– be due to HDAC-mediated silencing of genes required for an
optimal cell response to chemotherapy (such as Apaf-1) (Soengas
et al, 2001; Soengas and Lowe, 2003), and preclinical data suggest
that VPA should increase the sensitivity to chemotherapy.
According to this model, critical proapoptotic pathways (silenced
in cancer cells) should be reactivated following HDAC inhibition,
leading to apoptosis (Minucci and Pelicci, 2006).
Additionally, HDACis have been suggested to modulate the
immune response, through mechanisms which remain to be fully
elucidated (Guo et al, 2006). In some cases, HDACi treatment has
been proposed to potentiate immunoresponsive mechanisms,
based on the induction of MHC molecules (Kato et al, 2007).
Taken together, these indications offer a rationale for the
combination of HDACis with either standard chemotherapy or
with immunotherapeutic approaches.
We describe the results of a phase I/II clinical trial assessing the
activity of the combination of a standard chemoimmunotherapy
plus VPA in patients with advanced melanoma.
PATIENTS AND METHODS
Patients with histological diagnosis of locally advanced inoperable
or metastatic melanoma were eligible. Other selection criteria were
as follows: age 418 years and p75 years, ECOG performance
status 0–2, life expectancy of at least 6 months, measurable
disease, adequate bone marrow function (white blood cell count
43.0 10
9/l and platelet count 4100 10
9/l), adequate renal
function (serum creatinine o120mmoll
 1) and hepatic function
(serum bilirubin o 1.5mmoll
 1, AST o60UIl
 1), LDH levels p2
fold the upper normal limits, written informed consent. Exclusion
criteria were as follows: symptomatic cerebral or leptomeningeal
involvement, other malignancy except basal or squamous carci-
noma of the skin or in situ carcinoma of the cervix, non-malignant
systemic diseases that would prevent from undergoing any of the
treatment options, psychiatric or addictive disorders that would
prevent from giving informed consent, pregnancy or breastfeeding,
manifest severe hepatic and pancreatic dysfunction, porphyria,
previous chemoimmunotherapy within 40 days.
All patients signed an institutional review board-approved
informed consent form. The study was conducted in accordance
with the principles of the Helsinki Declaration.
Baseline evaluation included the following: medical history,
physical examination, ECOG performance status, haematology and
blood chemistry, ECG, chest X-ray or CT scan of the thorax, CT
scan or US of the abdomen. Target lesions were studied with CT
scan at baseline and for response evaluation.
Study design and treatment plan
The study has been originally designed as a phase II clinical trial,
with treatment plan involving an induction with VPA alone, whose
dosage was gradually increased in each patient until achieving
biologically active concentrations (‘optimal concentration’), and
then administered for 4 weeks, followed by a combined treatment
with chemoimmunotherapy plus VPA. The aim of the induction
phase was re-establishing the expression of genes, such as Apaf-1,
that have been shown to be silenced by HDAC-involving
mechanisms, and that are linked to response to chemotherapy
(Soengas et al, 2001). Because the main aim of the trial was the
evaluation of objective response to the combined treatment,
although no formal assessment of response to the induction phase
was planned, patients with overt disease progression during this
phase were taken off study and received treatment at the discretion
of the investigator.
We adopted a standard schedule of VPA administration used in
epileptic patients, starting with 10mgkg
 1day
 1 (in three divided
doses) and increasing the dose weekly by 10mgkg
 1day
 1 (with a
maximum allowed dose of 30mgkg
 1day
 1), up to the achieve-
ment of adequate plasmatic concentrations. These doses usually
allow to maintain steady-state plasma concentrations between 50
and 125mgl
 1 (DeVane, 2003), potentially in the range required to
modulate the target (HDACs). Prudent initial doses were chosen to
avoid haematological and neurological side effects that are dose
related and could be more unpredictable at higher doses, due to
the nonlinear metabolism/clearance and protein binding of VPA
(DeVane, 2003). Furthermore, the use of these doses of VPA as
anticonvulsant drug in association with chemotherapy in patients
with cerebral tumours had been reported as feasible, although a
slight increase in haematological toxicity is described (Bourg et al,
2001). Valproic acid was supplied in tablets from 200 and 500mg,
and total daily dose was rounded off to the nearest dose allowed by
the available tablets, and administered in three divided doses every
8h.
After 4 weeks of full dose VPA, patients received dacarbazine,
800mgm
 2 intravenously every 21 days, and interferon-a,
600.000IU twice daily subcutaneously, while continuing VPA at
the same dose. Treatment was planned for a maximum of four
courses of dacarbazine and 6 months of interferon-a, or until
disease progression. Antiemetic prophylaxis with serotonin
antagonists and corticosteroids was used before administering
dacarbazine.
The analysis of VPA plasmatic levels and histone acetylation
changes for the first 10 patients showed that the dose of
30mgkg
 1day
 1 did not allow either the achievement of the
optimal plasmatic concentration of free drug (50–100mgl
 1)i n
most patients or a consistent increase in histone acetylation. The
study design was therefore modified into a phase I/II clinical trial,
with an amendment to the protocol, introducing a second dose
level of maximum 90mgkg
 1day
 1 of VPA, based on plasmatic
levels achieved with the 30mgkg
 1day
 1 dose and on expected
toxicity (Figure 1). Seven patients who had already completed the
induction phase at 30mgkg
 1day
 1 as maximum dose had weekly
dose escalation by 30mgkg
 1day
 1 during the combination
phase, whereas new patients started the induction phase with
30mgkg
 1day
 1 and increased weekly by 30mgkg
 1 day
 1 until
the achievement of the required plasmatic concentration, which
was continued for 4 weeks alone and then in combination with
dacarbazine and interferon-a.
The primary end point was the response rate with the
combination of VPA plus chemoimmunotherapy. Secondary end
points were the assessment of the toxicity of VPA, alone and
combined with chemoimmunotherapy, the evaluation of clinical
benefit (defined as the overall rate of objective response plus
disease stabilisation longer than 24 weeks), response duration and
progression-free survival. Histone acetylation levels were mea-
sured in peripheral blood mononuclear cells (PBMCs) to assess
correlation with patient response.
Toxicity evaluation and dose modifications
Patients were assessed for toxicity weekly during the induction
with VPA alone and before every cycle of chemotherapy during the
combined treatment, with clinical examination and laboratory
evaluation. Toxicity was graded using the Common Toxicity
Criteria (CTC) Version 2.0 (http://ctep.cancer.gov/forms/
CTCv20_4-30-992.pdf), and common dose modifications or delays
were adopted for chemotherapy in case of toxicity. Valproate dose
was reduced (one step at a time, following the reverse of the
escalation plan for each dose level) in case of grade 2 toxicity
attributable to the drug, and temporarily stopped in case of grade
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then resumed with dose reduction as in case of grade 2 toxicity.
Response assessment
Assessment of response was done before each cycle of chemo-
therapy by physical examination in case of superficial lesions.
Computerized chemography for assessment of target lesions was
done after 8 weeks of combined therapy and repeated every 8
weeks thereafter (no assessment was planned at the end of the
induction period). Tumour response was defined according to
RECIST criteria (Therasse et al, 2000).
VPA plasma levels and histone acetylation in peripheral
blood cells
Measurement of VPA plasma levels (absolute and free levels) was
done at the end of the 1st week of treatment (four times daily: 0800
hours, before first daily administration; 1100 hours, 3h post-dose;
1500 hours, 7h post-dose; 1800 hours, 2h after the second daily
dose) and repeated at the beginning of the combination phase and
weekly thereafter (at 0800 hours, before first administration) or
whenever new drugs were introduced in the treatment of the
patient. To define the ‘optimal concentrations’ (biologically active
concentrations), we followed two criteria: (a) the plasmatic
concentrations of VPA. We measured both total and free levels
of the drug by FPIA method (fluorescence polarised immunoassay
– Abbott Industries). The free levels were performed on plasma
ultrafiltrates (Levy et al, 1984). Given the molecular weight and its
relatively low potency (Ki in the millimolar range), we aimed to
reach concentrations of free VPA in the millimolar range (50–
100mgl
 1 or higher); (b) the levels of induction of histone
acetylation in PBMCs. We used cytofluorimetric techniques to
evaluate histone acetylation levels in PBMCs, which in preclinical
models of acute myeloid leukaemia have been good indicators of
the efficacy of VPA treatment (Ronzoni et al, 2005). Assessments
were done at the end of the second week of treatment, at the
beginning of the combination phase and weekly thereafter. The
levels of histone acetylation in PBMCs from representative patients
are reported in Figure 2, together with results from a cell line
treated with trichostatin A as positive control.
Statistical considerations
The main end point was the best tumour response. Using a two
stage, phase II optimal design, powered to choose between an
acceptable response rate of 40% and an unacceptable one of 20%,
at the 5% significance level and 90% power, 19 patients were
needed in the first stage and if four or less had an objective
response than the trial had to be closed because of poor response.
If five or more patients had a response, the trial would go on to the
second stage by recruiting further 35 patients to reach a total of 54.
If 16 patients or more had an objective response, it could be
concluded that a response rate of 40% is possible and one of 20%
unlikely.
Because the main aim was to evaluate the overall activity of the
combination of VPA plus chemoimmunotherapy, the assessment
of treatment activity is performed on patients actually receiving
the combined treatment, but results of an intent-to-treat analysis
on all eligible patients are also reported.
Time-to-event end points were estimated using the method of
Kaplan and Meier. Progression-free survival was measured from
the first day of study treatment to the date of disease progression.
The association between paired continuous variables was assessed
by Spearman’s correlation coefficient. Statistical analysis was
performed with R (R Development Core Team, 2006).
RESULTS
Between September 2001 and February 2002, 32 patients referred
to the Division of Medical Oncology and to the Melanoma and
Muscle-Cutaneous Sarcoma Division of the European Institute of
Oncology were entered sequentially onto the study. Two patients
turned out to be ineligible, one with no evidence of disease and the
other because of a second malignancy. Among 30 eligible patients,
28 were assessable for toxicity, whereas one patient never started
treatment because of early refusal and one never reached
meaningful plasmatic levels of VPA because of malabsorption.
Eighteen patients received the combined treatment with VPA and
chemoimmunotherapy and were assessable for response. Ten
patients were not assessable, eight for early progressive disease
(before starting chemotherapy), one for non-compliance and one
who was admitted to another hospital and lost to follow-up. The
characteristics of all 32 registered patients are listed in Table 1.
Apart from most patients being pretreated for metastatic disease,
the distribution of main features is roughly comparable with that
from most recent large trials of first-line biochemotherapy (Eton
et al, 2002; Ridolfi et al, 2002; Bajetta et al, 2006).
Overall, 29 patients started the induction phase, receiving VPA
alone for a median duration of 6 weeks (range 3–10 weeks),
including dose escalation and 4 weeks at maximum dose. Eighteen
10 mg kg–1 day–1 20 mg kg–1 day–1 30 mg kg–1 day–1 (or maximum dose tolerated)
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Subsequent weeks 
Maximum dose 
tolerated and
 chemoimmunotherapy
30 mg kg–1 day–1 60 mg kg–1 day–1 90 mg kg–1 day–1 (or maximum dose tolerated) Maximum dose 
tolerated and
chemoimmunotherapy
1° VPA
dose level
2° VPA
dose level
Figure 1 Valproic acid dose escalation scheme. See the Patients and Methods section for a more detailed description of the treatment schedule and
rationale.
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spatients went on the combination phase, receiving a median of
four courses of chemotherapy (range 1–6) in association with
interferon-a, with 11 patients completing the planned programme
of four courses (one responsive patient received six courses of
chemotherapy).
Table 2 illustrates the amount of VPA received by patients,
reporting the maximum daily dose assumed and the median
duration of treatment at the maximum dose.
Among the initial cohort of 10 patients treated at the first dose
level of VPA, three did not undergo dose escalation above
10mgkg
 1day
 1, one for non-compliance and two because of
disease progression. The other seven reached the maximum dose
of 30mgkg
 1day
 1, but stopped treatment because of disease
progression before starting chemotherapy. In the second cohort of
patients, 15 reached a dose of VPA of 60mgkg
 1day
 1, without
further escalation because of toxicity, and four reached the
planned maximum dose of 90mgkg
 1day
 1, which was later
reduced or temporarily suspended in all of them; 11 completed the
planned treatment with VPA plus four courses of chemotherapy
and 6 months of interferon-a; the other eight patients stopped
treatment early, because of disease progression.
The median duration of treatment with an optimal dose of VPA
was less than 1 month. Table 3 shows the toxicity registered
according to the maximum dose of VPA. During the induction
phase, most side effects were mild and included myelosuppression,
gastrointestinal and hepatic toxicity and neurological toxicity;
more serious side effects were rare, and more likely due to disease
progression (see below). During the combination phase, myelo-
suppression was more severe. Most non-haematological side
effects were mild, but neurological toxicity exceeded that seen
during the induction phase.
Two patients had serious adverse events possibly related to
VPA. One had grade 4 cerebral haemorrhage, headache and coma,
and multiple grade 3 neurological symptoms and grade 3
hypocalcemia. Laboratory parameters, including coagulation tests,
were normal. An MRI of the brain showed a massive haemorrhage
in the right cerebral hemisphere; a neuroradiological consultant
favored the hypothesis of bleeding of a cerebral metastasis,
although the patient was not known to have cerebral metastases
before entering the study. The patient was taking VPA at the dose
of 60mgkg
 1day
 1; total VPA concentration was 148.9mgl
 1 and
free VPA concentration was 51mgl
 1. Histone acetylation in
peripheral blood leukocytes was increased 2.9 times over the
baseline values. Four days after suspension, VPA total and free
concentrations were dropped to 3.1 and 0.2mgl
 1, respectively.
The patient was also receiving dacarbazine and interferon-a.
Consciousness recovered to normal, but the patient had permanent
left hemiparesis.
A second patient had neurological toxicity (grade 3 confusion,
stupor, ataxia, urinary incontinence and grade 2 tremor) probably
related to VPA while taking a dose of 35mgkg
 1day
 1 plus
dacarbazine and interferon-a. Symptoms disappeared after sus-
pension of VPA.
Three other serious adverse events were considered unrelated to
the study treatment and attributed to tumour progression: one
case of pleural effusion with severe dyspnoea, one case of cachexia
and one case of grade 4 anaemia with haematuria due to melanoma
progression involving the bladder.
The two bleeding episodes reported (one cerebral haemorrhage
with combined therapy and one haematuria with VPA alone) could
suggest a possible bleeding diathesis, potentially related to the
interference of VPA with platelets and haemostasis, but this
possibility was not supported by alterations in common coagula-
tion tests.
The treatment produced one complete remission, two partial
remissions and three disease stabilisation lasting at least 24 weeks.
Twelve patients had progressive disease or short-term (2 months)
stabilisation, and 12 were not evaluable for response and were
considered as treatment failures. The overall response rate is thus
10% (95% CI: 2–27%) when considering all eligible patients
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Figure 2 (A) FACS analysis of reference U937 cells not treated and treated with 50ngml
 1 of trichostatin A (TSA) for 4h. The reference cells were
analysed at every measurement, to ensure consistency in machine settings and blank determination (see also Ronzoni et al, 2005). (B) Representative FACS
analyses of patients untreated or treated for 2 weeks with VPA. Peripheral blood mononuclear cells were collected and analysed as described in the Patients
and Methods section. Patients shown in the figure have been classified according to the level of increase in histone acetylation: absent (o2 fold), low (two-
to three-fold), moderate (43 fold).
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s(n¼30), and 17% (95% CI: 4–41%) when considering only
evaluable patients (n¼18). The rate of clinical benefit, in terms of
objective response or disease stabilisation lasting at least 24 weeks,
is 20.7% (95% CI: 8.0–39.7%) on all eligible patients and 33.3%
(95% CI: 13.3–59.0%) on evaluable patients. The median time to
progression (TTP) is 3.8 months.
The study was closed early for poor activity, after the enrolment
of 18 evaluable patients in the first stage, because only three
responses were seen by that time, while five or more responses
should have been registered among the first 19 patients to proceed
to the second stage. Most patients who obtained a clinical benefit
were pretreated with interferon-a as adjuvant (three patients) or
palliative (three patients) therapy; one patient who achieved
disease stabilisation was pretreated with dacarbazine for advanced
disease. The TTP has been for at least 40 weeks in four patients.
Plasmatic levels of total and free VPA were measured in 27
patients, and maximum levels reached are reported in Table 4.
There is a statistically significant correlation between VPA dose
and both total (Spearman’s R¼0.65, P¼0.0002) and free
(Spearman’s R¼0.63, P¼0.0005) VPA plasmatic levels, as well
as between increase in histone acetylation and both total (Spear-
man’s R¼0.44, P¼0.02) and free (Spearman’s R¼0.45, P¼0.02)
VPA plasmatic levels (Figure 3). On the contrary, there was no
clear association between dose and increase in histone acetylation
(Spearman’s R¼0.22, P¼0.3). There was no correlation between
histone acetylation and response. All patients who achieved greater
than twice increase in histone acetylation had disease progression
(data not shown).
DISCUSSION
Stage IV melanoma has a poor prognosis, with median survival
shorter than 1 year and a negligible proportion (p5%) of patients
alive at 5 years (Lee et al, 2000) after chemotherapy or
immunotherapy. Although dacarbazine is considered the standard
therapy, a meta-analysis of randomised trials showed a response
rate of 16.9% (95% CI: 14.7–19.1%) (Huncharek et al, 2001), and
randomised phase III trials with audited response assessment
yielded a response rate as low as 7% (Avril et al, 2004). Despite
encouraging results in phase II studies, neither polychemotherapy
(Chapman et al, 1999) nor biochemotherapy (Eton et al, 2002;
Ridolfi et al, 2002; Bajetta et al, 2006) have shown clear advantages
over single-agent dacarbazine in randomised trials. Therefore, new
therapeutic strategies are clearly needed.
Histone deacetylase inhibitors are considered among the most
promising new anticancer drugs, and several agents have recently
entered clinical trials. The use of HDACis has been suggested also
for the treatment of patients with melanoma (Boyle et al, 2005).
The use of VPA is extremely appealing. Although not as potent as
other HDACis developed more recently, this drug has been for
decades in the treatment of epilepsy, with generally mild side
effects reported. Valproic acid has been shown recently to be active
on melanoma cell lines, further suggesting a potential use in this
disease (Valentini et al, 2007). In our study, however, the
Table 1 Patient characteristics
Characteristic N
Sex
Male 17
Female 15
Age, years
Median 51
Range 23–72
ECOG performance status
02 6
15
21
Number of involved sites
01
1 (sc/ln) 6 (4/2)
29
421 6
Tumor site
M0 1
Skin, sc, ln 11
Lung 2
Other visceral/(CNS) 18/(2)
Previous treatments
Surgery 31
Adjuvant treatment
CT (DTIC) 1
IT (IF-a)1 2
None 19
Treatment for metastatic disease
CT (DTIC/CVD) 4 (4/1)
IT (IF-a)5
CT+IT 8
DTIC o CVD+IF-a (±IL-2) 7
DTIC o CVD+IL-2 1
Hyperthermic isolated limb perfusion 1
None 14
N. lines for metastatic disease
0/1/2/42 14/8/6/4
Median (range) 1 (0–5)
Abbreviations: sc¼subcutaneous; ln¼lymph nodes; CNS¼central nervous
system; ECOG¼Eastern Cooperative Oncology Group; CT¼chemotherapy;
IT¼immunotherapy; IF-a¼interferon-a; DTIC¼dacarbazine; CVD¼cisplatin
vinblastine dacarbazine.
Table 2 Maximum dose of valproic acid (VPA) received during the entire treatment period
a
Maximum VPA dose (mgkg
 1day
 1)
(First cohort, N¼10) (Second cohort, N¼19)
10 30 60 90
Number of patients 3 7 15 4
Median duration at maximum dose (days) 8 16 26 19
Temporary suspension (number of patients) 1 1 4 3
Dose reduction (number of patients) 1 4 5 3
Stopped VPA in advance (number of patients)
b 376 2
aOn 29 patients who actually started VPA assumption.
bFive serious adverse events, 1 non-compliance, 12 treatment failures.
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sTable 3 Toxicity of valproic acid (VPA)
a
NCI – CTC grade
12 3 4
VPA dose
(mgkg
 1day
 1)
No. of
patients
Median
duration
(weeks) Toxicity (No. of patients) (No. of patients)
(No. of
patients)
(No. of
patients)
VPA alone
10–30
b 17 6 Leukocytosis 2
Thrombocytosis 1
Anemia 2 2
Nausea/vomiting 2
Abdominal pain 1 1
Asthenia 3
Erithema 1
Hepatic (ALP, LDH) 1
Amylase 3 1
Dyspnea (pleural eff.) 1
Depr. consciousness 1
60–90
c 11 6 Thrombocytopenia 1
Anemia 1 1 1 1
d
Asthenia 1
Constipation 1
d
Sciatic pain 1
Infection 2
d
Creatinine 1
Hematuria 1
d
Hypoacusis 1
d
Dyspnoea 1
Ataxia 1
Depr. consciousness 1
d 1
VPA in combination with
chemoimmunotherapy
30 3 3 Anemia 1
Asthenia 2
Hepatic (AST) 1
Tremors 1
60 12 14 Leukopenia 2 4
Neutropenia 2 3
Thrombocytopenia 3 1 4
Anemia 2 3 1 1
Nausea/vomiting 6
Diarrhea 3 1
Asthenia 2
Ammonia 2
Hepatic (any) 3
Gastric pain 2
Fever 1 1
Hypocalcemia 1
Depr. consciousness 3 3 1 1
Other neurological
e 26 2 1
Cerebral hemorrhage 1
Urinary incontinence 1 1
90 3 3 Leukopenia 1
Thrombocytopenia 1 1
Anemia 1
Hepatic (AST) 1
Amylase 1
Headache 1
aOn 28 assessable patients. Each patient is reported in each section of the table (VPA alone, and VPA in combination with chemoimmunotherapy) within the row corresponding
to the highest dose level he received during the pertinent period of therapy. Some patients had dose reductions of VPA already during the induction phase, and others had dose
escalation during the combination phase. All patients except one had some kind of toxicity.
bThree patients at 10mgkg
 1day
 1, 14 patients at 30mgkg
 1day
 1.
c10 patients at
60mgkg
 1day
 1, one patient at 90mgkg
 1day
 1.
d90mgkg
 1day
 1, with bladder progression of disease.
eVertigo, hallucinations, headache, speech impairment, mood
alteration, memory loss, paraesthesia, seizures, tremors, confusion.
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scombination of dacarbazine, interferon-a and VPA did not appear
to be clearly superior in terms of activity to what is expected from
standard therapy.
The use of VPA as HDACi was hampered by a series of
problems. Valproic acid dosage must be adjusted gradually,
requiring a few weeks before reaching the full dose in most
patients, which may result in disease progression in aggressive
tumours. Eight patients in our study had early disease progression,
before starting chemotherapy. The drug turned out to be less
tolerable than when used alone for treatment of epilepsy,
particularly with dosages of 60mgkg
 1day
 1 or higher. The
median duration of treatment with an optimal dose of VPA was
less than 1 month, and most patients had dose reductions or
temporary interruption of treatment for toxicity. Two serious
adverse events, a grade 4 bleeding of a cerebral metastasis and a
grade 3 neurological toxicity, were possibly related to the study
drugs and required definitive interruption of VPA.
Preclinical studies have shown that indeed VPA inhibits
efficiently HDACs, and extended survival with tumour regression
in several cancer models (Insinga et al, 2005). A comparison of the
use of VPA in mice and human patients, however, reveals several
important differences. In fact, we were able to reach free plasmatic
concentrations of VPA 42m M in our mice models (4300mgl
 1
of free VPA) (Insinga et al, 2005). In contrast, only 44% of the
patients showed free VPA levels 430mgl
 1 (equivalent to a
concentration 40.2mM) and just three patients reached a free
VPA concentration 450mgl
 1 (40.3mM). These concentrations
are suboptimal, and the increase in histone acetylation levels
observed in PBMCs of the patients was never as high as those
observed in preclinical models. In fact, in murine models of
leukaemia, we were unable to achieve clinical responses (i.e.,
disease remission and extended survival) at free VPA levels below
1m M (A Insinga, PG Pelicci and S Minucci, unpublished
observations). At those levels, the average increase in histone
acetylation levels observed in blood-derived mononuclear cells
(which in leukaemic mice are a mix of leukaemic cells and PBMCs)
is always 44 fold, an increase which was not observed in this
clinical study. Only two patients showed a 44 fold increase in
histone acetylation, but those increases were not observed
throughout the entire treatment regimen, and therefore cannot
be considered as true exceptions to this model. In the absence of a
set of patients, which show sustained high levels of histone
acetylation following treatment, however, it cannot be claimed that
the relationship observed in the leukaemic murine models holds
true in the clinical setting, and further studies will be required.
From our study it appears difficult to further increase VPA
doses in continuous administration, without incurring in
undesired, serious side effects, at least when combined with
dacarbazine and interferon-a. Other studies have reported the
feasibility and partial activity of a continuous oral treatment with
lower doses of VPA of 30–40mgkg
 1day
 1 in combination with
hydralazine and chemotherapy (Arce et al, 2006; Candelaria et al,
2007), and the potential to improve results of chemotherapy alone
and to overcome chemotherapy resistance in solid tumours
(Candelaria et al, 2007). It is not possible to discern the relative
contribution of the two epigenetic drugs to these results, nor if the
addition of hydralazine could allow for a reduction in VPA doses
without jeopardising its activity. In our study, the mean plasmatic
level of total VPA in patients receiving doses p30mgkg
 1day
 1
was 88mgl
 1, producing a 1.7 mean fold increase in histone
acetylation, which is considered insufficient from preclinical data.
For patients receiving doses 430mgkg
 1day
 1, the mean
plasmatic concentration was 136mgl
 1 with a two-fold mean
increase in histone acetylation. Although we found a correlation
between VPA dose and plasmatic levels and between plasmatic
levels and histone acetylation changes, there was no significant
correlation between dose and histone acetylation changes.
Individual differences in VPA pharmacokinetics and pharmaco-
dynamics, related for example to baseline values of histone
acetylation and activity of HDACs, could explain the lack of a
direct relationship between VPA dose and biological activity,
which hampers the definition of the optimal dose of this agent.
Other studies have explored cyclic schedules. With an intravenous
administration of VPA daily for 5 consecutive days in 21-day
cycles (Atmaca et al, 2007), the MTD was 60mgkg
 1day
 1 and
histone hyperacetylation and HDAC downregulation were detected
on PBMCs in the majority of patients. The administration of a
loading dose (either intravenously or orally) of VPA followed by 5
oral doses administered every 12h, preceding the administration
Table 4 Plasmatic levels of total and free VPA
Total VPA plasmatic levels (mgl
 1) No. of patients
0–50 0
51–100 8
101–150 14
151–200 5
Free VPA plasmatic levels (mgl
 1) No. of patients
p10 4
10.1–20 7
20.1–30 4
30.1–40 7
40.1–50 2
50.1–60 3
Abbreviation: VPA¼valproic acid.
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Figure 3 Relationship between free (A) and total (B) valproic acid
(VPA) plasmatic levels and fold increase in histone acetylation in peripheral
blood mononuclear cells over baseline values. Data refer to the maximum
values of plasmatic VPA and the maximum fold increase in histone
acetylation reached by each patient during treatment at the maximal dose
of VPA. For a statistical analysis of the data, see the Results section. Note
that the patients who showed the highest increase in histone acetylation
levels (44 fold) did not maintain this increase at repeated measurements,
notwithstanding the maintenance of the VPA dose.
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sof epirubicin 75–100mgm
 2, allowed the achievement of
140mgkg
 1day
 1 as recommended dose of VPA for phase II
studies (Munster et al, 2007), showing a significant correlation
among histone H4 acetylation and VPA dose and plasmatic
concentration, as well as clinical antitumor activity.
Different administration schemes or combinations with other
chemotherapic regimens could play, therefore, an important role
in the determination of the response to VPA. Conflicting results
have been reported about the correlation among VPA dose,
plasmatic concentration and changes in histone acetylation, and
more data are needed to better define these relationships and the
value of these parameters as surrogate end points. The same
considerations could apply to other, more potent HDACis, such as
vorinostat and belinostat, which appear promising in enhancing
the activity of chemotherapy regimens (Ramalingam et al, 2007;
Sinha et al, 2007).
In conclusion, continuous oral treatment with VPA at doses of
60mgkg
 1day
 1 or greater seems not feasible in patients with
advanced melanoma receiving concomitant dacarbazine and
interferon-a. Administration of VPA with different schedules
(e.g., cyclically in concomitance with chemotherapy, or
continuously but at lower doses in concomitance with other
epigenetic or biological drugs), however, could be feasible and
treatment of a higher number of patients could reveal subsets of
responsive patients. Further development of VPA as HDACi in
patients with solid tumours requires careful consideration of the
treatment schedule, synergism with other drugs and ideally the
definition of predictors of response.
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